在妇科微创手术已较为成熟的今天，机器人平台的意义不宜被简单理解为对腹腔镜的替代。对多数常规病例而言，腹腔镜仍是稳定且成本相对可控的基本方案。结合本中心临床实践，笔者团队认为机器人最具代表性的应用场景主要包括：肥胖患者尤其是子宫内膜癌手术中的前哨淋巴结示踪与精准分期，严重肠粘连或深部浸润型内异症所致的复杂盆腹腔解剖重建，需精细缝合与重建的输尿管损伤修补或再植，以及大子宫切除中的精细解剖与重要脏器保护。笔者团队的体会是，腹腔镜是基础，机器人是复杂手术微创化的重要增益平台，其优势只有与严格的适应证选择、团队协作及流程标准化相结合，方能真正转化为患者的获益。未来推广应从适应证选择、团队协作、流程标准化、培训认证和安全边界等方面建立可复制路径，让机器人平台真正服务于复杂妇科手术的高质量微创化。

At a time when gynecologic minimally invasive surgery has become relatively mature, the significance of robotic platforms should not be simply understood as a replacement for laparoscopy. For most routine cases, laparoscopy remains a stable, accessible, and relatively cost-controllable basic approach. Based on our clinical experience, the most representative scenarios for robotic application include: sentinel lymph node (SLN) tracing and precise staging, especially in obese patients with endometrial cancer; complex pelvic-abdominal anatomical reconstruction due to severe intestinal adhesions or deeply infiltrating endometriosis (DIE); ureteral injury repair or reimplantation requiring delicate suturing and reconstruction; and precise anatomical dissection with vital organ protection during large uterus hysterectomy. We believe that laparoscopy serves as the foundation, while robotics acts as an important augmentation platform for miniinvasive treatment of complex surgeries. Only by combining the technical advantages of robotics with strict patient selection, team collaboration, and standardized procedures can it truly translate into patient benefits. Future implementation should emphasize indication selection, team collaboration, standardized workflow, credentialed training, and explicit safety boundaries so that the robotic platform can support high quality minimally invasive management of complex gynecologic surgery.